Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials

Neurology

Volumn 76, Issue 1 SUPPL. 1, 2011, Pages

  Bates, David ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; OLIGOCLONAL BAND; PLACEBO;

ARTICLE; BETA RHYTHM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICALLY ISOLATED SYNDROME; DIAGNOSTIC ACCURACY; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; HUMAN; IMMUNOTHERAPY; LOW DRUG DOSE; MULTIPLE SCLEROSIS; MYELITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK;

EID: 78751613188     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182050388     Document Type: Article

References (45)

1. Miller JR. The importance of early diagnosis of multiple sclerosis. J Manag Care Pharm 2004;10:S4-S11.
2. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998;51:682-689.
3. Comi G. Why treat early multiple sclerosis patients? Curr Opin Neurol 2000;13:235-240.
4. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-1438.
5. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005;4:281-288.
6. Traboulsee AL, Li DK. The role of MRI in the diagnosis of multiple sclerosis. Adv Neurol 2006;98:125-146.
7. Optic Neuritis Study Group. High-and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis. Arch Ophthalmol 2003;121:944-949.
8. O'Riordan JI, Thompson AJ, Kingsley DPE, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: 10-year follow-up. Brain 1998;121:495-503.
9. Masjuan J, Alvarez-Cermeno JC, Garcia-Barragan N, et al. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology 2006;66:576-578.
10. Miller DH. Brain atrophy, interferon beta, and treatment trials in multiple sclerosis. Lancet 2004;364:1463-1464.
11. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular in-terferon beta-1a therapy initiated during a first demyeli-nating event in multiple sclerosis: CHAMPS Study Group. N Engl J Med 2000;343:898-904.
12. Comi G, Filippi M, Barkhof F, et al. Effect of early inter-feron treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;35:1576-1582.
13. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-997.
14. Comi G, Martinelli V, Rodegher M, et al. Effect of glati-ramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-1511.
15. CHAMPS Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 2002;59:998-1005.
16. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after the first demyelinating event. Neurology 2006;66:678-684.
17. Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1489-1496.
18. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-1249.
19. Barkhof F, Polman CH, Radue EW, et al. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Arch Neurol 2007;64:1292-1298.
20. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-397.
21. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
22. PRISMS (Prevention of Relapses and Disability by Inter-feron beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
23. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial: The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655-661.
24. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis: The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998;43:79-87.
25. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS: Multiple Sclerosis Collaborative Research Group. Neurology 1999;53:1698-1704.
26. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial: The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-1276.
27. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:168-178.
28. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. In-terferon beta-1b in the treatment of multiple sclerosis. Final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
29. Paty D, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II: MRI analysis results of a mul-ticenter, randomized, double-blind, placebo-controlled trial: UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-667.
30. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of inter-feron beta-1a on neurologic disability in relapsing multiple sclerosis: The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1997;49:358-363.
31. PRISMS (Prevention of Relapses and Disability by Interferon-beta-1a Subcutaneously in Multiple Sclerosis) Study Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-1636.
32. Gold R, Rieckmann P, Chang P, Abdalla J. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. Eur J Neurol 2005;12:649-656.
33. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability: Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50:701-708.
34. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-297.
35. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-1460.
36. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002;59:1496-1506.
37. Mikol DD, Barkhof F, Chang P, et al, on behalf of the REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet 2008;7:903-914.
38. O'Connor P, Filippi M, Arnason BGW, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8:889-897.
39. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
40. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-1504.
41. Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63:1788-1795.
42. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679-687.
43. North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary multiple progressive multiple sclerosis. Neurology 2004;63:1788-1795.
44. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004;63:1779-1787.
45. Andersen O, Elovaara I, Fárkkilá M, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neu-rosurg Psychiatry 2004;75:706-710.